Candel Therapeutics (NASDAQ:CADL) Given New $10.00 Price Target at Credit Suisse Group

Candel Therapeutics (NASDAQ:CADLGet Rating) had its price objective reduced by Credit Suisse Group to $10.00 in a report published on Wednesday morning, Stock Target Advisor reports.

Candel Therapeutics Trading Down 3.8 %

NASDAQ CADL opened at $1.77 on Wednesday. Candel Therapeutics has a one year low of $1.47 and a one year high of $11.05. The company has a 50-day simple moving average of $2.52 and a 200-day simple moving average of $3.16. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.41 and a current ratio of 13.41. The firm has a market capitalization of $51.14 million, a PE ratio of -4.21 and a beta of 0.23.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. acquired a new position in Candel Therapeutics during the 2nd quarter valued at about $2,408,000. BlackRock Inc. boosted its stake in Candel Therapeutics by 15.5% during the 1st quarter. BlackRock Inc. now owns 132,322 shares of the company’s stock valued at $674,000 after purchasing an additional 17,708 shares during the period. Citadel Advisors LLC acquired a new position in Candel Therapeutics during the 3rd quarter valued at about $53,000. Empirical Asset Management LLC acquired a new position in Candel Therapeutics during the 1st quarter valued at about $61,000. Finally, Kestra Advisory Services LLC acquired a new position in Candel Therapeutics during the 1st quarter valued at about $64,000. 21.97% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

(Get Rating)

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

Further Reading

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.